vs
Side-by-side financial comparison of Curbline Properties Corp. (CURB) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $54.1M, roughly 1.1× Curbline Properties Corp.).
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
CURB vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $54.1M | $57.6M |
| Net Profit | $9.6M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | 17.8% | — |
| Net Margin | 17.6% | — |
| Revenue YoY | — | 94.1% |
| Net Profit YoY | — | 71.6% |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $54.1M | $57.6M | ||
| Q3 25 | $48.6M | $49.5M | ||
| Q2 25 | $41.4M | $39.5M | ||
| Q1 25 | $38.7M | $28.5M | ||
| Q4 24 | — | $29.7M | ||
| Q3 24 | $29.8M | $16.4M | ||
| Q2 24 | — | $7.3M |
| Q4 25 | $9.6M | — | ||
| Q3 25 | $9.4M | $-30.0M | ||
| Q2 25 | $10.4M | $-75.8M | ||
| Q1 25 | $10.6M | $-94.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-15.4M | $-85.6M | ||
| Q2 24 | — | $-91.4M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% |
| Q4 25 | 17.8% | — | ||
| Q3 25 | 19.3% | -30.8% | ||
| Q2 25 | 25.3% | -151.7% | ||
| Q1 25 | 27.6% | -276.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -51.8% | -433.0% | ||
| Q2 24 | — | -1055.4% |
| Q4 25 | 17.6% | — | ||
| Q3 25 | 19.2% | -60.5% | ||
| Q2 25 | 25.1% | -191.9% | ||
| Q1 25 | 27.3% | -330.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -51.8% | -523.3% | ||
| Q2 24 | — | -1248.6% |
| Q4 25 | $0.08 | — | ||
| Q3 25 | $0.09 | $-0.41 | ||
| Q2 25 | $0.10 | $-1.05 | ||
| Q1 25 | $0.10 | $-1.31 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.15 | $-1.32 | ||
| Q2 24 | — | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $289.6M | $130.0M |
| Total DebtLower is stronger | $423.2M | $209.1M |
| Stockholders' EquityBook value | $1.9B | $-438.2M |
| Total Assets | $2.5B | $259.1M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $289.6M | $130.0M | ||
| Q3 25 | $430.1M | $135.2M | ||
| Q2 25 | $429.9M | $149.6M | ||
| Q1 25 | $594.0M | $212.3M | ||
| Q4 24 | — | $297.3M | ||
| Q3 24 | $2.5M | $334.7M | ||
| Q2 24 | — | $276.2M |
| Q4 25 | $423.2M | $209.1M | ||
| Q3 25 | $396.4M | $207.1M | ||
| Q2 25 | $99.1M | $205.1M | ||
| Q1 25 | $99.0M | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M |
| Q4 25 | $1.9B | $-438.2M | ||
| Q3 25 | $1.9B | $-422.5M | ||
| Q2 25 | $1.9B | $-405.8M | ||
| Q1 25 | $1.9B | $-338.4M | ||
| Q4 24 | — | $-253.6M | ||
| Q3 24 | $1.1B | $-187.1M | ||
| Q2 24 | — | $-233.8M |
| Q4 25 | $2.5B | $259.1M | ||
| Q3 25 | $2.4B | $240.3M | ||
| Q2 25 | $2.1B | $250.2M | ||
| Q1 25 | $2.1B | $294.2M | ||
| Q4 24 | — | $378.3M | ||
| Q3 24 | $1.2B | $387.0M | ||
| Q2 24 | — | $319.4M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.6M | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | 13.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.6M | $-166.8M | ||
| Q3 25 | $39.2M | $-14.1M | ||
| Q2 25 | $34.2M | $-62.7M | ||
| Q1 25 | $25.4M | $-84.9M | ||
| Q4 24 | — | $-266.8M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.7M |
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | — | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.8M |
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | — | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | — | -966.2% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% |
| Q4 25 | 13.04× | — | ||
| Q3 25 | 4.19× | — | ||
| Q2 25 | 3.28× | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
